BeOne Medicines Ltd (fra:49BA) Share Price

Company Profile

Business description
BeOne Medicines Ltd is a holding company. Through its subsidiaries, it operates as an oncology-focused biopharmaceutical company engaged in the discovery and development of treatments for cancer. Its portfolio includes BRUKINSA (a Bruton's tyrosine kinase (BTK) inhibitor), sonrotoclax (a B-cell lymphoma 2 (BCL2) inhibitor, and a BTK chimeric degradation activation compound (BTK-CDAC). The company develops and commercializes wholly owned therapeutic assets targeting multiple mechanisms of action in oncology. The company operates in one segment: pharmaceutical products. It generates the majority of its revenue from the sale of its biopharmaceutical products.
Contact
c/o BeOne Medicines I GmbH
94 Aeschengraben 27
21st Floor
Basel4051
CHE
T: +41 616851900
E: [email protected]
https://www.beonemedicines.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
11,000

Recommended

Tech saw solid earnings, but there are more questions around which companies will benefit from AI, and which will be hurt.

Rachel Schlueter | 06 March 2026

A deep dive into the most traded stocks by Aussies in 2025 - and what this signals for the year ahead.

Tyger Fitzpatrick | 06 March 2026

How the most traded shares stack up against our analysts views.

Tyger Fitzpatrick | 04 March 2026

Index	Last price	Change	% Change
All Ordinaries	9,085.10	36.30	0.40%
CAC 40	7,993.49	52.31	-0.65%
DAX 40	23,591.03	224.72	-0.94%
Dow JONES (US)	47,501.55	453.19	-0.95%
FTSE 100	10,284.75	129.19	-1.24%
HKSE	25,757.29	435.95	1.72%
NASDAQ	22,387.68	361.31	-1.59%
Nikkei 225	55,620.84	342.78	0.62%
NZX 50 Index	13,519.35	98.54	-0.72%
S&P 500	6,740.02	90.69	-1.33%
S&P/ASX 200	8,851.00	25.80	0.29%
SSE Composite Index	4,124.19	15.63	0.38%